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Detection of Malignant Primary Hepatic
Neoplasms with Gadobenate Dimeglumine
(Gd-BOPTA) Enhanced T1-Weighted Hepatocyte
Phase MR Imaging: Results of Off-site Blinded
Review in a Phase-II Multicenter Trial
Objective: To investigate the efficacy of gadobenate dimeglumine (Gd-
BOPTA) enhanced MR imaging for the detection of liver lesions in patients with
primary malignant hepatic neoplasms.
Materials and Methods: Thirty-one patients with histologically proven primary
malignancy of the liver were evaluated before and after administration of Gd-
BOPTA at dose 0.05 or 0.10 mmol/kg. T1-weighted spin echo (T1W-SE) and gra-
dient echo (T1W-GRE) images were evaluated for lesion number, location, size
and confidence by three off-site independent reviewers and the findings were
compared to reference standard imaging (intraoperative ultrasound, computed
tomography during arterial portography or lipiodol computed tomography).
Results were analyzed for significance using a two-sided McNemar’s test.
Results: More lesions were identified on Gd-BOPTA enhanced images than on
unenhanced images and there was no significant difference in lesion detection
between either concentration. The largest benefit was in detection of lesions
under 1 cm in size (7 to 21, 9 to 15, 16 to 18 for reviewers A, B, C respectively).
In 68% of the patients with more than one lesion, Gd-BOPTA increased the num-
ber of lesions detected. 
Conclusion: Liver MR imaging after Gd-BOPTA increases the detection of
liver lesions in patients with primary malignant hepatic neoplasm.
arly detection of primary malignant tumors of the liver primarily hepato-
cellular carcinoma and cholangiocarcinoma remains a diagnostic challenge.
Ultrasonography (US), contrast enhanced computed tomography (CT) and
magnetic resonance (MR) imaging have shown suboptimal results particularly in the set-
ting of chronic liver disease (1 5). Although it has been hypothesized that tissue-specif-
ic contrast agents will improve the sensitivity of MR imaging for liver lesion detection,
to date only a few studies have reported results with hepatocyte directed contrast
agents (6 10). In this study we have investigated the value of gadobenate dimeglumine
(Gd-BOPTA) enhanced MR imaging in liver lesion detection based on an off-site evalu-
ation of images in patients with proven primary hepatic malignant neoplasms. 
MATERIALS AND METHODS
Patients
In a Phase II multicenter double-blind study of gadobenate dimeglumine (Gd-BOP-
TA; Bracco SpA, Milan, Italy), 113 adult patients with known or suspected liver mass-
es were examined. From this group, 31 patients with biopsy proven malignant primary
liver tumors (hepatocellular carcinoma in 29 and cholangiocarcinoma in 2) were iden-
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E
tified. There were 8 women and 23 men with a mean age
of 59 years (range 32 to 75 years). In 14 patients there was
biopsy or imaging evidence of cirrhosis. 
Based on a reference standard imaging, a total of 71 fo-
cal lesions were identified in these patients. The presence
and absence of a liver lesion was confirmed by intra opera-
tive ultrasound (IOUS) in 24 patients (48 lesions), comput-
ed tomography during arterial portography (CTAP) in 4
patients (15 lesions), and lipiodol CT (CTLP) in 3 patients
(8 lesions). All patients received at least one of these refer-
ence standard imaging studies of the liver within 7 days be-
fore to 14 days after the MR imaging. In patients with
more than one reference standard, IOUS was preferred
with CTAP being the next preferred examination. A cyst
and two focal areas of focal nodular hyperplasia were iden-
tified and excluded from further analysis. 
Contrast Agent
Gadobenate dimeglumine is an octadentate chelate of
gadolinium which may be used as a non-specific contrast
agent like the conventional gadolinium agents as well as a
liver-specific contrast agent (11). The chemical and phar-
macodynamic properties of this contrast agent have been
described previously (12 16). In brief, following rapid (2
ml/min) intravenous injection of the contrast agent, it ini-
tially redistributes into the extracellular space and is then
largely eliminated by the kidneys. Some 3-5% of the in-
jected dose is however taken up by functioning hepato-
cytes and undergoes biliary excretion. Despite the low per-
centage of hepatobiliary excretion, the fraction taken up
produces clinically useful hepatic enhancement that in-
creases liver signal-to-noise ratio (SNR) and liver-to-lesion
contrast-to-noise ratio (CNR) (6 8, 14). Peak enhance-
ment of lesion-to-liver contrast occurs between 40 and 120
minutes. Since one goal of the clinical trial was to deter-
mine optimal dose, one of two different doses were inject-
ed in a blinded fashion. The contrast agent (either 0.25
mmol/L or 0.5 mmol/L solution) was administered intra-
venously at 10 ml/min immediately after the unenhanced
MR examination. Seventeen patients received 0.05
mmol/kg, and 14 patients received 0.10 mmol/kg. Post
contrast imaging was performed at two delayed time points
in order to determine the optimal imaging period in the he-
patocyte phase.
MR Imaging
MR imaging was performed at 1.5 Tesla with T1-weight-
ed spin echo (SE) and T1-weighted gradient echo (GRE)
pulse sequences before contrast administration as well as
40 80 minutes (early) and 90 120 minutes (late) after
contrast administration. The liver was imaged with 10-14
axial 10 mm thick sections with 2 mm gaps; a matrix size of
140 160 256, and a tailored field of view ranging from
285 350 380 400 mm. T1-weighted SE sequences uti-
lized a repetition time between 350-550 msec and an echo
time of 15 msec and 3 4 excitations. The T1-weighted
GRE images were acquired with a repetition time of 95
150 msec, a 4 msec echo time, an 800 flip angle and one ex-
citation during a single breath hold. T2 weighted images
were also obtained but were not included in the analysis.
Image Analysis
Three off-site independent reviewers (A, B, C) evaluated
the MR images separately in a random unpaired fashion
that included the pre contrast images and the post contrast
images. Each set of MR images was evaluated individually
and the number, size, and location by surgical segment of
lesions were recorded on liver maps. Additionally, each re-
viewer, using a 5-point scale system, documented the con-
fidence with which a lesion was detected. A point of 1 indi-
cated that the lesion was definitely present, a point of 2 in-
dicated that a lesion was probably present while a point of
3 indicated an indeterminate lesion. Point of 4 and 5 indi-
cated that a lesion was probably not present or definitely
not present respectively.
Each reviewer assessed the presence of lesions for each
patient at each time point for each sequence. The total
number of lesions as well as their size and location was de-
termined from the reference standard imaging. In a patient
with multiple lesions, no more than five lesions per patient
were assessed in order not to bias the findings toward pa-
tients with multiple lesions. Subsequently, the five largest
lesions from the reference standard imaging were ana-
lyzed. This allowed inclusion of all patients without skew-
ing the data from the patients with many lesions. A lesion
was considered present if the reviewer confidence ranking
was either a 1 or 2 point (definitely or probably present).
False positive lesions were defined as lesions reported by
the reviewers with a confidence of 1 or 2 with no corre-
sponding lesion by the reference standard. Analysis ac-
cording to lesion size was performed by dividing the le-
sions into three groups based on diameter size: 1 cm or
less; between 1 cm to 2 cm; and greater than 2 cm. 
Statistical Analysis
The efficacy of gadobenate dimeglumine enhanced MRI
was evaluated by assessing the change in detection (rela-
tive to the reference standard) from pre-contrast MRI to
contrast enhanced MRI. The change in concordance with
the reference standard from unenhanced to enhanced MRI
in the determination of the number of focal liver lesions
was tested using a two tailed McNemars test. A p-value of
Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging in Malignant Primary Hepatic Neoplasms
Korean J Radiol 2(4), December 2001 211
0.05 or less was considered statistically significant.
Differences in concordance were also studied between con-
centrations and imaging times using a two tailed
McNemars test. Because all patients were selected on the
basis of lesion pathology, specificity and accuracy could
not be assessed. 
RESULTS
The number of focal liver lesions identified on Gd-BOP-
TA enhanced MR images exceeded the number identified
on unenhanced images (Table 1). Table 1 separates the
number of lesions identified by reviewer by time point as
well as by imaging sequence. By combining both the T1-
weighted GRE and T1-weighted SE images before and af-
ter contrast (both early and late time points) for reviewers
A, B and C, the number of lesions identified increased af-
ter contrast administration from 34 to 53, 37 to 48, and 43
to 49, respectively. This difference was statistically signifi-
cant for 2 of the 3 reviewers (p<0.05). There was no signif-
icant difference in lesion detection between the two con-
centrations (0.05 mmol/kg and 0.10 mmol/kg) of contrast
administered. Table 1 shows that, in general, more lesions
were identified with the T1-weighted GRE pulse sequence
when compared to the T1-weighted SE technique, and
more lesions were identified after contrast administration
when both imaging techniques were analyzed together.
Most lesions were identified on the late imaging time point
(90-120 minutes) although several more lesions (total num-
ber) were identified combining both the early and late
post-contrast images. 
The number of false positive lesions decreased for two of
the three reviewers after the administration of Gd-BOPTA
(Table 2). There were 15 patients with solitary lesions. One
reviewer detected all of these lesions while the other two
reviewers detected 14 out of 15 solitary lesions. The ad-
ministration of contrast was not needed to identify any of
these solitary lesions. There were 5 patients with 2 lesions;
both lesions were identified only after contrast administra-
tion in 4 of the 5 patients. In the remaining patient with
two lesions, the second lesion (25 mm) was not identified
before or after contrast. In two of these patients gadobe-
nate dimeglumine administration allowed identification of
the second lesion while in the other two patients, Gd-BOP-
TA administration was required for the visualization of
both (Fig. 1). There were 3 patients with 3 lesions. One le-
sion was identified before and after gadobenate dimeglu-
mine in all of these patients; however, the second and third
lesions were only identified by one of the reviewers in one
patient and two reviewers in another patient. In the third
patient with three lesions, one reviewer detected the sec-
ond and third lesion only without contrast administration.
There were 3 patients with 4 lesions and 5 patients with 5
lesions. Two out of three reviewers detected more lesions
after contrast administration in 6 out of these 8 patients
(Fig 2). In the remaining two patients, one patient had no
Pena et al.
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Table 2. False Positive Liver Lesions Detected
Reviewer A Reviewer B Reviewer C
Pre Contrast 6 2 7
Post Contrast 3 4 5
Table 1. Liver Lesion Detected by Each Reviewer
Reviewer A Reviewer B Reviewer C
T1W- T1W- Both T1W- T1W- Both T1W- T1W- Both
SE GRE SE GRE SE GRE
Pre Contrast 17 18 18 21 18 22 23 24 25
0.05 Early Post Contrast 24 24 26 17 20 20 21 24 25
mmol/kg Late Post Contrast 24 26 28 20 22 24 25 23 28
n = 40 Both Post Contrast 27 27 28 20 24 24 26 25 28
Pre Contrast 12 16 16 13 15 15 17 16 18
0.10 Early Post Contrast 14 21 21 14 23 23 18 20 20
mmol/kg Late Post Contrast 16 23 25 15 22 23 13 17 18
n = 31 Both Post Contrast 18 23 25 17 24 24 19 20 21
Pre Contrast 29 34 34 34 33 37 40 40 43
Both doses Early Post Contrast 38 45 47 31 43 43 39 44 45
n = 71 Late Post Contrast 40 49 53 35 44 47 38 40 46
Both Post Contrast 45 50 53 37 48 48 45 45 49
Note. p < 0.05 when compared to pre-contrast images using two tailed McNemar s test, All lesions as correlated with reference standard imaging
additional lesions identified while only 1 out of the 3 re-
viewers detected more lesions after contrast in the other
patient. In 68% of the patients with more than one lesion
by reference standard (11 of 16 patients), more lesions
were identified by 2 of the 3 reviewers on contrast en-
hanced images.
After contrast administration, smaller lesions were better
detected by two of the three reviewers (Table 3). From a
total of 29 lesions smaller than 1 cm, the number of lesions
detected before and after contrast infusion for reviewers
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Fig. 2. 72 year-old woman with hepatocellular carcinoma.
A. T1-weighted SE image before contrast demonstrates a large lesion within segment 2-3.
B. T1-weighted SE image performed 90 minutes after injection of 0.05 mmol/kg of gadobenate dimeglumine better delineates a second
lesion within segment 4 (arrow). Note even though there is enhancement of the tumor, the lesion to liver contrast still increases.
A B
Fig. 1. 61 year-old man with hepatocellular carcinoma. 
A. T1-weighted GRE image without contrast demonstrates a small segment 8 lesion (arrow).
B. T1-weighted GRE image after injection of 0.1 mmol/kg of gadobenate dimeglumine shows increased conspicuity of the segment 8 le-
sion (arrow).
A B
Table 3. Detection of Liver Lesions by Size
Reviewer A Reviewer B Reviewer C
Pre Post Pre Post Pre Post
< 1 cm 7 20 9 15 16 18
(n=29) (24%) (69%) (31%) (52%) (55%) (62%)
1 2 cm 3 9 3 7 3 7
(n= 14) (21%) (64%) (21%) (50%) (21%) (50%)
> 2 cm 24 24 25 26 24 24
(n=28) (86%) (86%) (89%) (93%) (86%) (86%)
A, B, and C where 7 to 21, 9 to 15, and 16 to 18 respec-
tively. This was statistically significant (p<0.05) for only
two of the three reviewers (Fig 3). The number of lesions
detected for both the 1 2 cm and greater than 2 cm group
also increased after contrast administration.
DISCUSSION
This study shows that gadobenate dimeglumine en-
hanced T1-weighted MR imaging can improve the detec-
tion of primary hepatic malignant neoplasms. Our findings
confirm prior reports that have noted improvement in le-
sion-liver contrast on Gd-BOPTA enhanced images.
Furthermore, our findings show that the most important
benefit is in the detection of small (less than 1 cm) tumors. 
Prior reports have provided conflicting findings on con-
trast enhanced MR imaging using hepatocyte targeted con-
trast agents in patients with cirrhosis. For example,
Murakami et al. noted that compared to normal liver, pa-
tients with cirrhosis had lower hepatic enhancement with
Mn-DPDP (9) while Manfredi et al. reported similar en-
hancement between normal and cirrhotic livers with
gadobenate dimeglumine (6). These differences may be
due to variations in the severity of cirrhosis in the subject
groups or due to differences in pharmacokinetics of the
two drugs as Gd-BOPTA also shows non-specific tissue en-
hancement (extracellular effect) in addition to hepatocyte
specific liver enhancement. The differentiation of the he-
patic neoplasm may also be important.
Our results have important implications with respect to
imaging technique and the evaluation of patients with pri-
mary hepatic neoplasms. Firstly T1-weighted GRE tech-
niques were superior compared to SE techniques and there
was only minimal improvement in the total number of le-
sions detected when both sequences were used together.
Prior studies have in fact reported that quantitative mea-
surement of liver-to-lesion contrast on T1-weighted GRE
images is superior to that on SE images (17). This advan-
tage is most likely related to greater T1-weighting on the
GRE images due to the availability of shorter TEs and to
decreased motion-related noise in these breath-hold im-
ages. Thus liver imaging with gadobenate dimeglumine
should be performed with short TE GRE techniques. These
images can also be obtained at thinner section (8 mm) with
ample coverage to study the entire liver. While use of fat-
saturation may also provide additional benefit, this was not
studied and requires future attention (18).
In terms of the optimal imaging window, it appears there
is a favorable distinction between liver and primary malig-
nant hepatic neoplasms at both the early and late time
points after gadobenate dimeglumine administration al-
though slightly more total lesions were detected at the late
time point (90 120 minutes after injection). There was no
significant difference in lesion detection between the two
doses (0.05 mmol/kg and 0.10 mmol/kg) evaluated. One
possible way to image with this agent is to initially perform
dynamic imaging immediately following the pre-contrast
examination (not performed in these cases) and then, if
needed, have the patient return at a convenient time be-
tween 1 2 hours later to have delayed scans performed.
Pena et al.
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Fig. 3. 35 year-old woman with hepatocellular carcinoma.
A. T1-weighted GRE image before contrast demonstrates large primary lesion.
B. T1-weighted GRE image performed 90 minutes after injection of 0.05 mmol/kg of gadobenate dimeglumine better identifies the large
primary tumor but also of smaller lesions within the right lobe.
A B
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This approach may not only increase the yield in lesion de-
tection in patients with cirrhosis where dynamic scanning is
known to be of critical importance, but may also provide
important perfusion data for tissue characterization.
Moreover, this approach may well be the preferred proce-
dure in patients suspected of harboring liver metastases. In
such patients, dynamic imaging with conventional gadolini-
um agents does not necessarily improve lesion detectability
over unenhanced scans alone (19 20). 
There are several limitations to our study. The popula-
tion studied was limited because only patients with known
neoplasms were evaluated. This did not allow determina-
tion of accuracy, sensitivity or specificity since there was
an unintentional bias as the reviewers expected to identify
at least one hepatic mass. In addition the off-site analysis
methodology may also have biased the results against Gd-
BOPTA since clinical information may have improved di-
agnostic performance was not available. Furthermore, the
presence of cirrhosis was not proven in all subjects; it is
likely that this patient population represented a spectrum
of underlying chronic liver disease and extrapolation to a
cirrhotic population should be made with caution. Another
limitation was that even though histological diagnosis was
available for all the patients, not every lesion was sampled.
Finally, comparison of this agent to contrast-enhanced heli-
cal CT may also be necessary to determine the clinical utili-
ty of gadobenate dimeglumine enhanced liver MR imaging.
Clinical utility may also be affected by the fact that the T2-
weighted images were not utilized for the evaluation of the
images. This methodology was adopted in order to best
evaluate the effect of the contrast agent on T1-weighted
images. However, in actual practice, patients would not be
evaluated without simultaneous review of the T2-weighted
images.
In conclusion, Gd-BOPTA may serve a role as a contrast
agent to identify primary malignant hepatic neoplasms
with MR imaging. From our blinded off-site multicenter
evaluation, the contrast agent aids in the detection of
smaller lesions in a patient group where traditional imaging
(US, CT, MR) has been limited.
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